Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047807 · ClinicalTrials.gov registry record · NA
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07047807: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT07047807 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07047807, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
Interventions
- OTHER Usual Care
- BEHAVIORAL PDAC-PATHWAYS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-06 |
| Est. Completion | 2027-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07047807
The ClinicalTrials.gov registry entry for NCT07047807 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT07047807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07047807 about?
NCT07047807 is a clinical study titled "PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma". This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT07047807?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-10-06. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07047807?
The interventions under investigation include: Usual Care (OTHER), PDAC-PATHWAYS (BEHAVIORAL).
Who is sponsoring clinical trial NCT07047807?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.